Re-treatment of relapsed Paget's disease of bone with zoledronic acid: results from an open-label study
Ian R Reid, Jacques P Brown, Naomi Levitt, José A Román Ivorra, Javier Bachiller-Corral, Ian L Ross, Guoqin Su, Oscar Antunez-Flores, R Paul Aftring, Ian R Reid, Jacques P Brown, Naomi Levitt, José A Román Ivorra, Javier Bachiller-Corral, Ian L Ross, Guoqin Su, Oscar Antunez-Flores, R Paul Aftring
Abstract
Six patients from the phase 3 trials of zoledronic acid in Paget's disease, who had received zoledronic acid initially and had subsequently relapsed, were entered into an open re-treatment study. Following re-treatment, each patient reached similar absolute nadirs of serum alkaline phosphatase to those recorded after their first dose. No significant adverse events were reported. It is concluded that, while re-treatment of Paget's disease with zoledronic acid is rarely needed, it is safe and effective, with no evidence of treatment resistance based on this small cohort.
Conflict of interest statement
IRR has acted as a consultant for Novartis. GS, OA-F and RPA are Novartis employees. The remaining authors declare no conflict of interest.
Figures
Source: PubMed